New blood test tracks progression of Alzheimer’s disease
Researchers unveil a new blood test that measures Alzheimer’s progression in the brain, announced at a major clinical trials conference in Boston.
Key Takeaways
AIResearchers have announced a new blood test that helps reveal the progression of Alzheimer’s disease in the brain, during their participation at the Clinical Trials on Alzheimer’s Disease conference in Boston, Massachusetts.
The test, developed by Alamar Biosciences, measures levels of a biomarker called EMTPR-tau, which reflects the accumulation of twisted tau protein tangles in brain cells.
Current blood tests for Alzheimer’s disease measure proteins such as beta-amyloid and phosphorylated tau, which rise in the early stages of the disease, but provide only limited information about tau protein tangles in later stages.
There are two Alzheimer’s drugs on the market designed to reduce beta-amyloid plaques in the brain, but several other medications in development target tau protein.
Dr. Niklas Mattsson-Carlgren, lead researcher from Lund University in Sweden, said in a statement: “One of the most difficult tasks in diagnosing Alzheimer’s disease is proving that the disease is not only present in someone with cognitive impairment, but that it is at an advanced enough stage to potentially explain the symptoms.”
The researchers noted in a report published in the Journal of the American Medical Association (JAMA) that the new blood test is not yet available for clinical use and is not intended to diagnose Alzheimer’s disease on its own.
Nicholas Ashton, a study co-leader from the Banner Sun Health Research Institute in Sun City, Arizona, said in a statement: “Having a simple yet highly scalable way to determine the extent of tau protein tangles in the brain is a major step forward in our understanding of Alzheimer’s disease.”
Ashton added that current blood tests, together with the new EMTPR-tau test, could help doctors make better treatment decisions and identify suitable patients for clinical trials.
